Please Wait
Applying Filters...
menu
    • menu
    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    SPI Pharma has been solving formulation challenges using superior functional materials.

    Virtual Booth

    Contact Supplier

    Interquim comes from an international group of 50 companies active in the pharma, hospital, diagnostics, fine chemicals & feed sectors.

    Virtual Booth

    Contact Supplier

    Cohance Lifesciences, offers full range of CDMO services for small molecule APIs, intermediates, ADCs, Pellets and Formulations.

    Virtual Booth

    Contact Supplier

    FAMAR CDMO- From early development to commercial manufacturing.

    Virtual Booth

    Contact Supplier

    Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

    Virtual Booth

    Contact Supplier

    Menu

    Jtk 303

    ACTIVE PHARMA INGREDIENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DRUG PRODUCT COMPOSITIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    FDA Confirms Paragraph IV Patent Litigation for Elvitegravir, Cobicistat, Emtricitabine, Tenofovir Alafenamide Tablets
    FDA Confirms Paragraph IV Patent Litigation for Elvitegravir, Cobicistat, Emtricitabine, Tenofovir Alafenamide Tablets

    15 Jun 2023

    // FDA

    https://www.pharmacompass.com/pdf/news/fda-confirms-paragraph-iv-patent-litigation-for-elvitegravir-cobicistat-emtricitabine-tenofovir-alafenamide-tablets-59973.pdf

    FDA
    15 Jun 2023
    Share Share
    Stribild (elvitegravir) Japan Tobacco v. Mylan Pharma
    Stribild (elvitegravir) Japan Tobacco v. Mylan Pharma

    29 Jan 2019

    // PATENT LITIGATION

    https://insight.rpxcorp.com/litigation_documents/13210791

    PATENT LITIGATION
    29 Jan 2019
    Share Share
    California reports show drug spending changes as 2 companies sue over disclosure
    California reports show drug spending changes as 2 companies sue over disclosure

    03 Jan 2019

    // Ed Silverman STAT NEWS

    https://www.statnews.com/pharmalot/2019/01/03/california-drug-prices-transparency-4/?utm_source=STAT+Newsletters&utm_campaign=b0cc66a241-Pharmalittle_COPY_01&utm_medium=email&utm_term=0_8cab1d7961-b0cc66a241-150630089

    Ed Silverman STAT NEWS
    03 Jan 2019
    Share Share
    China National Drug Administration Approves Gilead's Genvoya
    China National Drug Administration Approves Gilead's Genvoya

    06 Aug 2018

    // PRESS RELEASE

    http://www.gilead.com/news/press-releases/2018/8/china-national-drug-administration-approves-gileads-genvoya-elvitegravir-cobicistat-emtricitabine-and-tenofovir-alafenamide-a-single-tablet-regimen-for-the-treatment-of-hiv1-infection

    PRESS RELEASE
    06 Aug 2018
    Share Share
    Truvada® (emtricitabine & tenofovir disoproxil fumarate)elvitegravir, GS 9350 (cobicistat): ViiV Healthcare v. Gilead Sciences
    Truvada® (emtricitabine & tenofovir disoproxil fumarate)elvitegravir, GS 9350 (cobicistat): ViiV Healthcare v. Gilead Sciences

    07 Feb 2018

    // PATENT LITIGATION

    https://www.pharmacompass.com/pdf/news/truvada-emtricitabine-tenofovir-disoproxil-fumarateelvitegravir-gs-9350-cobicistat-viiv-healthcare-v-gilead-sciences-1518416906.pdf

    PATENT LITIGATION
    07 Feb 2018
    Share Share
    Gilead’s genvoya shows significantly higher rates of virologic suppression
    Gilead’s genvoya shows significantly higher rates of virologic suppression

    15 Feb 2017

    // PHARMABIZ

    http://www.pharmabiz.com/NewsDetails.aspx?aid=100403&sid=2

    PHARMABIZ
    15 Feb 2017
    Share Share